All In Biotech

Drug Trial Radar · NCT06507306

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

92

Actual

Start

Jun 3, 2024

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Kumquat Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Conditions

  • Solid Tumor, Adult

Interventions

  • KQB198Drug

    Oral KQB198

  • OsimertinibDrug

    Oral Osimertinib

  • AmivantamabDrug

    Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)Time frame: 28 Days
  2. Recommended Phase 2 Dose (RP2D) (Part 1)Time frame: up to 30 months
  3. Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Parts 2 and 3)Time frame: up to 30 months

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona -

    Orlando, Florida

  • Florida Cancer Specialists - Sarasota

    Sarasota, Florida

  • Henry Ford Health System

    Detroit, Michigan

  • David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center

    Long Island City, New York

  • The Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, Ohio

  • Sarah Cannon and HCA Research Institute

    Nashville, Tennessee

  • New Experimental Therapeutics of San Antonio - NEXT Oncology

    San Antonio, Texas

  • New Experimental Therapeutics of Virginia - NEXT Oncology

    Fairfax, Virginia

  • Institut Paoli-Calmettes

    Marseille, Bouches-du-Rhône, France

  • Institut de Cancerologie de l'Ouest - site St-Herblain

    Saint-Herblain, Loire-Atlantique, France

  • CHU Bordeaux - Hopital Saint-Andre

    Bordeaux, Nouvelle-Aquitane, France

  • IUCT-Oncopole

    Toulouse, Occitaine, France

  • CHU de Nantes - Hopital Nord Laennec

    Nantes, Pays de la Loire Region, France

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Lazio, Italy

  • New Experimental Therapeutics (NEXT) Oncology Barcelona

    Barcelona, Spain

  • South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC

    Madrid, Spain

  • New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid

    Madrid, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Quirónsalud Málaga

    Málaga, Spain

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, Spain

  • Hospital Universitari Quiron Dexeus Barcelona

    Barcelona, Catalonia, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.